Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model

Peter H Kvist, Lars Svensson, Oskar Hagberg, Vibeke Hoffmann, Kaare Kemp, Mads A Røpke, Peter H Kvist, Lars Svensson, Oskar Hagberg, Vibeke Hoffmann, Kaare Kemp, Mads A Røpke

Abstract

The aim of the present study was to compare the effects of Daivobet and calcipotriol on clinical score and biomarker responses in a modified version of the Scholtz-Dumas psoriasis plaque assay. Furthermore, it was the aim to compare the effects of calcipotriol and betamethasone in the murine psoriasis xenograft model. Twenty four patients with psoriasis were treated topically once daily for three weeks, whereas the grafted mice were treated for four weeks. Clinical responses were scored twice weekly and biopsies were taken at the end of each study to analyse for skin biomarkers by histology and immunohistochemistry. The results clearly demonstrate effects on both clinical signs and biomarkers. In the patient study the total clinical score was reduced significantly with both Daivobet and calcipotriol. Both treatments reduced epidermal thickness, Ki-67 and cytokeratin 16 expression. T cell infiltration was significantly reduced by Daivobet but only marginally by calcipotriol. Both treatments showed strong effects on the epidermal psoriatic phenotype.Results from the xenograft model essentially showed the same results. However differences were observed when investigating subtypes of T cells.The study demonstrates the feasibility of obtaining robust biomarker data in the psoriasis plaque test that correlate well with those obtained in other clinical studies. Furthermore, the biomarker data from the plaque test correlate with biopsy data from the grafted mice.

Figures

Figure 1
Figure 1
Percent reduction (mean ± SEM, n = 12) in total clinical score (TCS) from day 1 to day 22 after treatment with Daivobet® vehicle, calcipotriol and Daivobet® once daily 6 times weekly (excl. Sunday) for three weeks.
Figure 2
Figure 2
Correlation between biomarker responses and total clinical score in skin samples from psoriasis patients treated for three weeks with ointment vehicle. Correlation of clinical score with epidermal thickness (A; r = 0.733), CD3 positive T cells (B; r = 0.375), Ki-67 positive cells (C; r = 0.675) or cytokeratin 16 positive cells (D; r = 0.628).
Figure 3
Figure 3
Biomarker endpoints after treatment with vehicle (A, D, G and J), calcipotriol (B, E, H and K) and Daivobet® (C, F, I and L) in the psoriasis plaque assay. A-C: Masson-Trichrome (MT) staining showing epidermal hyperplasia. D-F: Proliferation of keratinocytes in stratum basale of epidermis (Ki-67). G-I: Immunohistochemical staining with a pan-T cell marker (CD3). J-L: Epidermal expression of keratin 16 show decrease after treatment with calcipotriol and is absent after treatment with Daivobet®.
Figure 4
Figure 4
Immunohistochemical stainings of a keratome biopsy before (A, B and C) transplantation and after (D, E and F) transplantation and treatment in the psoriasis xenograft SCID mouse. Before transplantation the expression of CD3 (A), CD4 (B) and CD8 (C) is seen in follicular structures and diffusely distributed in the skin. However, the intensity of CD4 expression is slightly decreased compared to freshly excised and fixed psoriatic skin (data not shown). Five weeks after transplantation including a three week treatment with vehicle the expression of CD3 (D) expression in the skin seems to be increased. In contrast, CD4 (E) and CD8 (F; arrows) expression is down regulated after vehicle treatment. The skin from A, B, C, D, E and F is from the same donor.

References

    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi: 10.1016/S0140-6736(07)61128-3.
    1. Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol. 1972;52(1):43–48.
    1. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, Winkel JG van de. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112(10):1571–1580.
    1. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150(6):1167–1173. doi: 10.1111/j.1365-2133.2004.05986.x.
    1. Guenther L, Kerkhof PC van de, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323. doi: 10.1046/j.1365-2133.2002.04967.x.
    1. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393. doi: 10.1159/000066440.
    1. Pacifico A, Daidone R, Peris K. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol. 2006;20(2):153–157. doi: 10.1111/j.1468-3083.2006.01387.x.
    1. Reichrath J, Muller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol. 1997;36(1):19–28. doi: 10.1016/S0190-9622(97)70320-7.
    1. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211. doi: 10.1038/sj.jid.5701213.
    1. Jensen AM, Llado MB, Skov L, Hansen ER, Larsen JK, Baadsgaard O. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol. 1998;139(6):984–991. doi: 10.1046/j.1365-2133.1998.02553.x.
    1. de Jong EM, Kerkhof PC van de. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. Br J Dermatol. 1991;124(3):221–229. doi: 10.1111/j.1365-2133.1991.tb00565.x.
    1. Glade CP, van Erp PE, Kerkhof PC van de. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study. Br J Dermatol. 1996;135(3):379–384. doi: 10.1111/j.1365-2133.1996.tb01499.x.
    1. Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol. 2001;144(Suppl 58):27–32.
    1. Berth-Jones J, Fletcher A, Hutchinson PE. Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol. 1992;126(4):356–361. doi: 10.1111/j.1365-2133.1992.tb00678.x.
    1. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, Kerkhof PC van de. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol. 2004;13(2):106–112. doi: 10.1111/j.0906-6705.2004.00151.x.
    1. Vissers WH, van VI, van Erp PE, de Jong EM, Kerkhof PC van de. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol. 2008;158(4):705–712. doi: 10.1111/j.1365-2133.2008.08442.x.
    1. Korver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, Kerkhof PC van de. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol. 2007;156(1):130–137. doi: 10.1111/j.1365-2133.2006.07561.x.
    1. Boehncke WH, Schon MP. Animal models of psoriasis. Clin Dermatol. 2007;25(6):596–605. doi: 10.1016/j.clindermatol.2007.08.014.
    1. Sugai J, Iizuka M, Kawakubo Y, Ozawa A, Ohkido M, Ueyama Y, Tamaoki N, Inokuchi S, Shimamura K. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci. 1998;17(2):85–92. doi: 10.1016/S0923-1811(97)00077-7.
    1. Villadsen LS, Skov L, Dam TN, Dagnaes-Hansen F, Rygaard J, Schuurman J, Parren PW, Winkel JG van de, Baadsgaard O. In situ depletion of CD4+ T cells in human skin by Zanolimumab. Arch Dermatol Res. 2007;298(9):449–455. doi: 10.1007/s00403-006-0710-0.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する